Biopharma

관련학술자료

Immune Monitoring Outcomes of Patients with Stage III/IV Melanoma Treated with a Combination of Pembrolizumab and Intratumoral Plasmid Interleukin 12 (pIL-12)

운영자 2018.09.10

첨부파일 | ASCO-SITC-ONCS-Presentation-Handout.pdf 다운로드

Immune Monitoring Outcomes of Patients with Stage III/IV Melanoma Treated with a Combination of Pembrolizumab and Intratumoral Plasmid Interleukin 12 (pIL-12)

ASCO-SITC 2017